CHANNEL THERAPEUTICS CORP (CHRO) Stock Income Statement
NYSEARCA:CHRO - American Stock Exchange - US1711261057 - Common Stock
| TTM (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 199.90K | |||
| Operating Expenses | 7.88M | 6.86M | 2.32M | 839.00K | 1.55M | |||
| Research and Development | 2.86M | 2.58M | 391.70K | 209.10K | 138.60K | |||
| Selling, General, and Administrative Expenses | 5.02M | 4.28M | 1.93M | 630.00K | 1.42M | |||
| Operating Income | -7.88M | -6.86M | -2.32M | -839.00K | -1.35M | |||
| Interest Income/Expense | -1.09M | -518.51K | -140.40K | 243.60K | -1.70K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | 695.00K | |||
| Income Before Taxes | -8.98M | -7.38M | -2.46M | -595.40K | -660.60K | |||
| Net Income | -8.98M | -7.38M | -2.46M | -595.40K | -660.60K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.67 | -1.28 | -0.43 | -0.10 | -0.11 | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | N/A | -330.47% | |||
| Operating Profit Margin | N/A | N/A | N/A | N/A | -677.29% | |||
All data in USD